Modeling of HIV‐1 prophylactic efficacy and toxicity with islatravir shows non‐superiority for oral dosing, but promise as a subcutaneous implant

• Autori principali: Hee‐yeong Kim (Autore), Lanxin Zhang (Autore), Craig W. Hendrix (Autore), Jessica E. Haberer (Autore), Max vonKleist (Autore)
• Natura: Libro
• Pubblicazione: Wiley, 2024-10-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Abstract HIV prevention with pre‐exposure prophylaxis (PrEP) constitutes a major pillar in fighting the ongoing epidemic. While daily oral PrEP adherence may be challenging, long‐acting (LA‐)PrEP in oral or implant formulations could overcome frequent dosing with convenient administration. The novel...